Pillar Financial Advisors’s NovoCure NVCR Stock Holding History

Pillar Financial Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-138	Closed	-$1.78K	–	120
2025 Q3	$1.78K	Hold	138	–	–	﹤0.01%	107
2025 Q2	$2.46K	Hold	138	–	–	﹤0.01%	95
2025 Q1	$2.46K	Hold	138	–	–	﹤0.01%	97
2024 Q4	$4.11K	Buy	+138	New	+$2.92K	﹤0.01%	89

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Pillar Financial Advisors's NVCR Position: Q4 2025 in Review

Pillar Financial Advisors sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 138 shares — an estimated $1.78K sold.

Pillar Financial Advisors first reported a position in NVCR in Q4 2024 and held it in 4 quarters. The position peaked at $4.11K in Q4 2024. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Pillar Financial Advisors reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Pillar Financial Advisors sold 138 NovoCure shares in Q4 2025, an estimated $1.78K.
Pillar Financial Advisors first reported a position in NovoCure in Q4 2024 and held it in 4 quarters.
Pillar Financial Advisors's NovoCure position peaked at $4.11K in Q4 2024.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Pillar Financial Advisors's 13F filing for Q4 2025, filed 2 Feb 2026.